XML 48 R26.htm IDEA: XBRL DOCUMENT v3.20.4
Major Customers, Partnerships and Strategic Alliances (Tables)
 12 Months Ended
Dec. 31, 2020
Kite Pharma, Inc. ("Kite")  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues recognized under agreement
Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202020192018
Revenue related to Kite agreement:
Recognition of license and stand-ready fee$25,046 $24,977 $18,545 
Research services3,562 9,373 6,972 
Total$28,608 $34,350 $25,517 
Pfizer, Giroctocogene Fitelparvovec  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues recognized under agreement
Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202020192018
Revenue related to Pfizer giroctocogene fitelparvovec agreement:
Recognition of upfront fee and research services$3,111 $15,697 $37,810 
Milestone achievement31,338 23,662 — 
Total$34,449 $39,359 $37,810 
Pfizer C9ORF72  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues recognized under agreement
Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202020192018
Revenue related to Pfizer C9ORF72 agreement:
Recognition of upfront fee$7,985 $1,827 $2,188 
Milestone achievement5,000 — — 
Total$12,985 $1,827 $2,188 
During the year ended December 31, 2020, the Company recorded adjustments to revenue related to changes in estimate in connection with the C9ORF72 collaboration agreement with Pfizer. These adjustments were a direct result of the decision to decrease the project scope and the corresponding costs due to advancement of the program, which resulted in an increase in the measure of proportional cumulative performance. These adjustments increased revenue by $8.8 million, decreased net loss by $8.8 million and decreased the Company’s basic net loss per share by $0.06 for the year ended December 31, 2020.
Sanofi  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues recognized under agreement
Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202020192018
Revenue related to Sanofi agreement:
Recognition of upfront fee$298 $3,494 $4,013 
Research services4,823 6,367 9,503 
Milestone achievement201 12,819 — 
Total$5,322 $22,680 $13,516